A

Austin Research Center for Retina | Austin, TX

Research site
(Unclaimed)
Location
3705 Medical Parkway, Suite 465, Austin, Texas, United States of America
Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

7 of 13
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
Fenofibrate for Prevention of DR Worsening (Protocol AF)

This randomized trial will evaluate the effect of fenofibrate compared with placebo for prevention of diabetic retinopathy (DR) worsening through 6 y...

Enrolling
Diabetic Retinopathy
Other: Placebo
Drug: Fenofibrate

Evaluate the safety and efficacy of transpalpebral microcurrent stimulation (MCS) therapy for patients with nonexudative (dry) age-related macular de...

Enrolling
Age-Related Macular Degeneration
Nonexudative Age-related Macular Degeneration
Device: i-Lumen(TM) AMD Sham
Device: i-Lumen(TM) AMD

This Phase 2 study is conducted to investigate the safety and efficacy of runcaciguat in the treatment of diabetic retinopathy. To assess efficacy, t...

Active, not recruiting
Diabetic Retinopathy
Drug: Runcaciguat (BAY1101042)
Other: Placebo

RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AM...

Enrolling
Wet Age-related Macular Degeneration
Wet AMD
Genetic: RGX-314
Biological: Ranibizumab (LUCENTIS®)

This is a first in-human study to investigate the safety, tolerability and efficacy of zifibancimig administered through intravitreal (IVT) injection...

Enrolling
Macular Degeneration
Drug: Zifibancimig
Device: Port Delivery Platform

This phase 2a trial is a randomized, open-label, parallel-group study in approximately 60 patients with DME to evaluate the efficacy and safety of CU...

Active, not recruiting
Diabetic Macular Edema
Drug: CU06-1004
Locations recently updated

This study will evaluate the efficacy, safety, and pharmacokinetics of the Port Delivery System with Ranibizumab (PDS) in Participants with Diabetic...

Active, not recruiting
Diabetic Macular Edema
Drug: Intravitreal Ranibizumab 0.5 mg Injection
Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab

Trial conditions

Edema (6 trials)
Macular Edema (6 trials)
Diabetic Retinopathy (3 trials)
Macular Degeneration (3 trials)
Retinal Diseases (2 trials)
Dissociative Disorders (1 trial)
Epiretinal Membrane (1 trial)
Geographic Atrophy (1 trial)
Retinal Detachment (1 trial)
Retinal Vein Occlusion (1 trial)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems